{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:51:04Z","timestamp":1762955464555},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,7,14]],"date-time":"2015-07-14T00:00:00Z","timestamp":1436832000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s00595-015-1218-z","type":"journal-article","created":{"date-parts":[[2015,7,13]],"date-time":"2015-07-13T18:42:29Z","timestamp":1436812949000},"page":"161-168","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Neoadjuvant treatment for locally advanced rectal cancer: a systematic review"],"prefix":"10.1007","volume":"46","author":[{"given":"Keisuke","family":"Uehara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Nagino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,14]]},"reference":[{"key":"1218_CR1","first-page":"277","volume":"22","author":"RJ Heald","year":"1979","unstructured":"Heald RJ. A new approach to rectal cancer. Br J Hosp Med. 1979;22:277\u201381.","journal-title":"Br J Hosp Med"},{"key":"1218_CR2","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/S0140-6736(86)91510-2","volume":"1","author":"RJ Heald","year":"1986","unstructured":"Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1:1479\u201382.","journal-title":"Lancet"},{"key":"1218_CR3","first-page":"335","volume":"181","author":"WE Enker","year":"1995","unstructured":"Enker WE, Thaler HT, Cranor ML, Polyak T. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg. 1995;181:335\u201346.","journal-title":"J Am Coll Surg"},{"key":"1218_CR4","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJM199704033361402","volume":"336","author":"Swedish Rectal Cancer Trial","year":"1997","unstructured":"Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336:980\u20137.","journal-title":"N Engl J Med"},{"key":"1218_CR5","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1056\/NEJMoa010580","volume":"345","author":"E Kapiteijn","year":"2001","unstructured":"Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638\u201346.","journal-title":"N Engl J Med"},{"key":"1218_CR6","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731\u201340.","journal-title":"N Engl J Med"},{"key":"1218_CR7","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1200\/JCO.2005.08.144","volume":"23","author":"J Folkesson","year":"2005","unstructured":"Folkesson J, Birgisson H, Pahlman L, et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol. 2005;23:5644\u201350.","journal-title":"J Clin Oncol"},{"key":"1218_CR8","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","volume":"30","author":"R Sauer","year":"2012","unstructured":"Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926\u201333.","journal-title":"J Clin Oncol"},{"key":"1218_CR9","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.sla.0000257358.56863.ce","volume":"246","author":"KC Peeters","year":"2007","unstructured":"Peeters KC, Marijnen CA, Nagtegaal ID, Dutch Colorectal Cancer Group, et al. The TME trial after a median follow-up of 6\u00a0years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246:693\u2013701.","journal-title":"Ann Surg"},{"key":"1218_CR10","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","volume":"12","author":"W Gijn van","year":"2011","unstructured":"van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575\u201382.","journal-title":"Lancet Oncol."},{"key":"1218_CR11","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","volume":"24","author":"JP G\u00e9rard","year":"2006","unstructured":"G\u00e9rard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620\u20135.","journal-title":"J Clin Oncol"},{"key":"1218_CR12","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/bjs.5506","volume":"93","author":"K Bujko","year":"2006","unstructured":"Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215\u201323.","journal-title":"Br J Surg"},{"key":"1218_CR13","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s00595-013-0811-2","volume":"44","author":"J Hida","year":"2014","unstructured":"Hida J, Okuno K, Tokoro T. Distal dissection in total mesorectal excision, and preoperative chemoradiotherapy and lateral lymph node dissection for rectal cancer. Surg Today. 2014;44:2227\u201342.","journal-title":"Surg Today"},{"key":"1218_CR14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10147-015-0801-z","volume":"20","author":"T Watanabe","year":"2015","unstructured":"Watanabe T, Itabashi M, Shimada Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207\u201339.","journal-title":"Int J Clin Oncol"},{"key":"1218_CR15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(13)70599-0","volume":"15","author":"JF Bosset","year":"2014","unstructured":"Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184\u201390.","journal-title":"Lancet Oncol."},{"key":"1218_CR16","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S1470-2045(14)70377-8","volume":"15","author":"YS Hong","year":"2014","unstructured":"Hong YS, Nam BH, Kim KP, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014;15:1245\u201353.","journal-title":"Lancet Oncol"},{"key":"1218_CR17","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","volume":"355","author":"JF Bosset","year":"2006","unstructured":"Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114\u201323.","journal-title":"N Engl J Med"},{"key":"1218_CR18","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1200\/JCO.2009.25.8541","volume":"28","author":"C Fern\u00e1ndez-Martos","year":"2010","unstructured":"Fern\u00e1ndez-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol. 2010;28:859\u201365.","journal-title":"J Clin Oncol"},{"key":"1218_CR19","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1200\/JCO.2009.22.0467","volume":"27","author":"MS Roh","year":"2009","unstructured":"Roh MS, Colangelo LH, O\u2019Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27:5124\u201330.","journal-title":"J Clin Oncol"},{"key":"1218_CR20","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1007\/BF02234784","volume":"44","author":"H Nagawa","year":"2001","unstructured":"Nagawa H, Muto T, Sunouchi K, et al. Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy. Dis Colon Rectum. 2001;44:1274\u201380.","journal-title":"Dis Colon Rectum"},{"key":"1218_CR21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1067\/msy.2002.125357","volume":"132","author":"T Watanabe","year":"2002","unstructured":"Watanabe T, Tsurita G, Muto T, et al. Extended lymphadenectomy and preoperative radiotherapy for lower rectal cancers. Surgery. 2002;132:27\u201333.","journal-title":"Surgery"},{"key":"1218_CR22","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00066-010-2205-3","volume":"187","author":"H Numasaki","year":"2011","unstructured":"Numasaki H, Shibuya H, Nishio M, et al. Japanese structure survey of radiation oncology in 2007 with special reference to designated cancer care hospitals. Strahlenther Onkol. 2011;187:167\u201374.","journal-title":"Strahlenther Onkol"},{"key":"1218_CR23","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.ijrobp.2009.10.019","volume":"78","author":"T Teshima","year":"2010","unstructured":"Teshima T, Numasaki H, Shibuya H, et al. Japanese structure survey of radiation oncology in 2007 based on institutional stratification of patterns of care study. Int J Radiat Oncol Biol Phys. 2010;78:1483\u201393.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1218_CR24","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1200\/JCO.2005.05.256","volume":"23","author":"CA Marijnen","year":"2005","unstructured":"Marijnen CA, van de Velde CJ, Putter H, et al. Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol. 2005;23:1847\u201358.","journal-title":"J Clin Oncol"},{"key":"1218_CR25","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2005.14.779","volume":"23","author":"KC Peeters","year":"2005","unstructured":"Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients\u2014a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199\u2013206.","journal-title":"J Clin Oncol"},{"key":"1218_CR26","doi-asserted-by":"crossref","first-page":"8697","DOI":"10.1200\/JCO.2005.02.9017","volume":"23","author":"H Birgisson","year":"2005","unstructured":"Birgisson H, P\u00e5hlman L, Gunnarsson U, et al. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol. 2005;23:8697\u2013705.","journal-title":"J Clin Oncol"},{"key":"1218_CR27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s10350-005-0296-1","volume":"49","author":"J Pollack","year":"2006","unstructured":"Pollack J, Holm T, Cedermark B, et al. Long-term effect of preoperative radiation therapy on anorectal function. Dis Colon Rectum. 2006;49:345\u201352.","journal-title":"Dis Colon Rectum"},{"key":"1218_CR28","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/DCR.0b013e31819739a0","volume":"52","author":"M Ito","year":"2009","unstructured":"Ito M, Saito N, Sugito M, et al. Analysis of clinical factors associated with anal function after intersphincteric resection for very low rectal cancer. Dis Colon Rectum. 2009;52:64\u201370.","journal-title":"Dis Colon Rectum"},{"key":"1218_CR29","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/cncr.25217","volume":"116","author":"JD Wright","year":"2010","unstructured":"Wright JD, St Clair CM, Deutsch I, et al. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer. 2010;116:2486\u201392.","journal-title":"Cancer"},{"key":"1218_CR30","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1200\/JCO.2005.02.543","volume":"23","author":"H Birgisson","year":"2005","unstructured":"Birgisson H, P\u00e5hlman L, Gunnarsson U, Glimelius B. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol. 2005;23:6126\u201331.","journal-title":"J Clin Oncol"},{"key":"1218_CR31","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(09)60484-0","volume":"373","author":"D Sebag-Montefiore","year":"2009","unstructured":"Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811\u201320.","journal-title":"Lancet"},{"key":"1218_CR32","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","volume":"27","author":"S Kopetz","year":"2009","unstructured":"Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677\u201383.","journal-title":"J Clin Oncol"},{"key":"1218_CR33","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.ijrobp.2011.05.027","volume":"82","author":"SJ Wong","year":"2012","unstructured":"Wong SJ, Winter K, Meropol NJ, et al. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2012;82:1367\u201375.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1218_CR34","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2010.34.4911","volume":"29","author":"C Aschele","year":"2011","unstructured":"Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773\u201380.","journal-title":"J Clin Oncol"},{"key":"1218_CR35","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.2009.25.8376","volume":"28","author":"JP G\u00e9rard","year":"2010","unstructured":"G\u00e9rard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12\/0405-Prodige 2. J Clin Oncol. 2010;28:1638\u201344.","journal-title":"J Clin Oncol"},{"key":"1218_CR36","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.2013.53.7753","volume":"32","author":"MJ O\u2019Connell","year":"2014","unstructured":"O\u2019Connell MJ, Colangelo LH, Beart RW, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32:1927\u201334.","journal-title":"J Clin Oncol"},{"key":"1218_CR37","unstructured":"Schmoll HJ, Haustermans K, Price T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: first results of the PETACC-6 randomized phase III trial. J Clin Oncol. 2013;31(suppl). Abstract, p. 3531."},{"key":"1218_CR38","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1470-2045(12)70187-0","volume":"13","author":"C R\u00f6del","year":"2012","unstructured":"R\u00f6del C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO\/ARO\/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13:679\u201387.","journal-title":"Lancet Oncol"},{"key":"1218_CR39","unstructured":"R\u00f6del C, Liersch T, Fietkau R, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-04 randomized phase III trial. J Clin Oncol. 2014;32(suppl):5s. Abstract, p. 3500."},{"key":"1218_CR40","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1200\/JCO.2012.42.8771","volume":"30","author":"JP G\u00e9rard","year":"2012","unstructured":"G\u00e9rard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12\/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30:4558\u201365.","journal-title":"J Clin Oncol"},{"key":"1218_CR41","unstructured":"Allegra CJ, Yothers G, O\u2019Connell MJ, et al. Final results from NSABP protocol R-04: Neoadjuvant chemoradiation (RT) comparing continuous infusion (CIV) 5-FU with capecitabine (Cape) with or without oxaliplatin (Ox) in patients with stage II and III rectal cancer. J Clin Oncol. 2014;32(suppl):5s. Abstract, p. 3603."},{"key":"1218_CR42","unstructured":"Schmoll HJ, Haustermans K, Price T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis. J Clin Oncol. 2014;32:5s(suppl). Abstract, p. 3501."},{"key":"1218_CR43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ijrobp.2014.09.031","volume":"91","author":"SJ Wong","year":"2015","unstructured":"Wong SJ, Moughan J, Meropol NJ, et al. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2015;91:116\u201323.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1218_CR44","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ijrobp.2009.11.007","volume":"79","author":"T Sato","year":"2011","unstructured":"Sato T, Ozawa H, Hatate K, et al. A Phase II trial of neoadjuvant preoperative chemoradiotherapy with S-1 plus irinotecan and radiation in patients with locally advanced rectal cancer: clinical feasibility and response rate. Int J Radiat Oncol Biol Phys. 2011;79:677\u201383.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1218_CR45","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijrobp.2014.03.007","volume":"89","author":"T Nakamura","year":"2014","unstructured":"Nakamura T, Yamashita K, Sato T, et al. Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors. Int J Radiat Oncol Biol Phys. 2014;89:547\u201355.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1218_CR46","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1200\/JCO.2005.04.4875","volume":"24","author":"I Chau","year":"2006","unstructured":"Chau I, Brown G, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol. 2006;24:668\u201374.","journal-title":"J Clin Oncol"},{"key":"1218_CR47","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(09)70381-X","volume":"11","author":"YJ Chua","year":"2010","unstructured":"Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:241\u20138.","journal-title":"Lancet Oncol."},{"key":"1218_CR48","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1093\/annonc\/mdr473","volume":"23","author":"R Mar\u00e9chal","year":"2012","unstructured":"Mar\u00e9chal R, Vos B, Polus M, et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol. 2012;23:1525\u201330.","journal-title":"Ann Oncol"},{"key":"1218_CR49","doi-asserted-by":"crossref","first-page":"513","DOI":"10.6004\/jnccn.2014.0056","volume":"12","author":"A Cercek","year":"2014","unstructured":"Cercek A, Goodman KA, Hajj C, et al. Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw. 2014;12:513\u20139.","journal-title":"J Natl Compr Canc Netw"},{"key":"1218_CR50","unstructured":"National comprehensive cancer network: NCCN clinical practice guidelines in oncology. Rectal cancer v.2. http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/rectal.pdf (2015). Accessed 10 May 2015."},{"key":"1218_CR51","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.radonc.2007.11.025","volume":"87","author":"C Radu","year":"2008","unstructured":"Radu C, Berglund A, P\u00e5hlman L, Glimelius B. Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study. Radiother Oncol. 2008;87:343\u20139.","journal-title":"Radiother Oncol"},{"key":"1218_CR52","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.radonc.2009.04.007","volume":"92","author":"P Hatfield","year":"2009","unstructured":"Hatfield P, Hingorani M, Radhakrishna G, et al. Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol. 2009;92:210\u20134.","journal-title":"Radiother Oncol"},{"key":"1218_CR53","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/bjs.7796","volume":"99","author":"D Pettersson","year":"2012","unstructured":"Pettersson D, Holm T, Iversen H, et al. Preoperative short-course radiotherapy with delayed surgery in primary rectal cancer. Br J Surg. 2012;99:577\u201383.","journal-title":"Br J Surg"},{"key":"1218_CR54","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1471-2407-13-279","volume":"13","author":"PJ Nilsson","year":"2013","unstructured":"Nilsson PJ, van Etten B, Hospers GA, et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer\u2013the RAPIDO trial. BMC Cancer. 2013;13:279. doi: 10.1186\/1471-2407-13-279 .","journal-title":"BMC Cancer"},{"key":"1218_CR55","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ejso.2010.05.017","volume":"36","author":"Y Ishii","year":"2010","unstructured":"Ishii Y, Hasegawa H, Endo T, et al. Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer. Eur J Surg Oncol. 2010;36:1061\u20135.","journal-title":"Eur J Surg Oncol"},{"key":"1218_CR56","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.2013.51.7904","volume":"32","author":"D Schrag","year":"2014","unstructured":"Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol. 2014;32:513\u20138.","journal-title":"J Clin Oncol"},{"key":"1218_CR57","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/jjco\/hyt115","volume":"43","author":"K Uehara","year":"2013","unstructured":"Uehara K, Hiramatsu K, Maeda A, et al. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 phase II trial. Jpn J Clin Oncol. 2013;43:964\u201371.","journal-title":"Jpn J Clin Oncol"},{"key":"1218_CR58","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00280-014-2417-9","volume":"73","author":"J Hasegawa","year":"2014","unstructured":"Hasegawa J, Nishimura J, Mizushima T, et al. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. Cancer Chemother Pharmacol. 2014;73:1079\u201387.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1218_CR59","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1007\/s00595-013-0686-2","volume":"44","author":"Y Yoshioka","year":"2014","unstructured":"Yoshioka Y, Uehara K, Ebata T, et al. Postoperative complications following neoadjuvant bevacizumab treatment for advanced colorectal cancer. Surg Today. 2014;44:1300\u20136.","journal-title":"Surg Today"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-015-1218-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00595-015-1218-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-015-1218-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T14:05:45Z","timestamp":1559138745000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00595-015-1218-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,14]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["1218"],"URL":"https:\/\/doi.org\/10.1007\/s00595-015-1218-z","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,14]]}}}